Journal Article A retrospective multicenter study of carbon-ion radiotherapy for major salivary gland carcinomas: subanalysis of J-CROS 1402 HN

Hayashi, Kazuhiko  ,  Koto, Masashi  ,  Demizu, Yusuke  ,  Jun-ichi, Saitoh  ,  Suefuji, Hiroaki  ,  Okimoto, Tomoaki  ,  Ohno, Tatsuya  ,  Shioyama, Yoshiyuki  ,  Takagi, Ryo  ,  Ikawa, Hiroaki  ,  Nemoto, Kenji  ,  Nakano, Takashi  ,  Kamada, Tadashi

2018-03 , 日本癌学会
A retrospective multicenter study was conducted to assess the clinical outcomes of carbon-ion radiotherapy for head and neck malignancies (Japan Carbon-Ion Radiation Oncology Study Group [J-CROS] study: 1402 HN). We evaluated the safety and efficacy of carbon-ion radiotherapy in patients with major salivary gland carcinoma. Sixty-nine patients treated with carbon-ion radiotherapy at 4 Japanese institutions were analyzed. Thirty-three patients (48%) had adenoid cystic carcinomas, 10 (14%) had mucoepidermoid carcinomas, and 26 (38%) had other disease types. Three patients (4%) had T1 disease, 8 (12%) had T2, 25 (36%) had T3, and 33 (48%) had T4. The median radiation dose was 64 Gy (relative biological effectiveness) in 16 fractions. The median gross tumor volume was 27 mL. The median follow-up period was 32.7 months. The 3-year local control rate and overall survival rate were 81% and 94%, respectively. Regarding acute toxicities, 7 patients had grade 3 mucositis and 7 had grade 3 dermatitis. Regarding late toxicities, 1 patient had grade 3 dysphagia and 1 had a grade 3 brain abscess. No grade 4 or worse late reactions were observed. In conclusion, definitive carbon-ion radiotherapy was effective with acceptable toxicity for major salivary gland carcinomas.

Number of accesses :  

Other information